CN118317771A - 用于局部治疗布鲁里溃疡中的溃疡分枝杆菌的制剂和方法 - Google Patents

用于局部治疗布鲁里溃疡中的溃疡分枝杆菌的制剂和方法 Download PDF

Info

Publication number
CN118317771A
CN118317771A CN202280079174.4A CN202280079174A CN118317771A CN 118317771 A CN118317771 A CN 118317771A CN 202280079174 A CN202280079174 A CN 202280079174A CN 118317771 A CN118317771 A CN 118317771A
Authority
CN
China
Prior art keywords
clofazimine
pharmaceutical composition
topical pharmaceutical
composition according
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280079174.4A
Other languages
English (en)
Chinese (zh)
Inventor
托马斯·霍夫曼
布兰登·巴纳舍夫斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Mannkind Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mannkind Corp filed Critical Mannkind Corp
Publication of CN118317771A publication Critical patent/CN118317771A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280079174.4A 2021-11-30 2022-11-29 用于局部治疗布鲁里溃疡中的溃疡分枝杆菌的制剂和方法 Pending CN118317771A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163284426P 2021-11-30 2021-11-30
US63/284,426 2021-11-30
PCT/US2022/080537 WO2023102363A1 (en) 2021-11-30 2022-11-29 Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers

Publications (1)

Publication Number Publication Date
CN118317771A true CN118317771A (zh) 2024-07-09

Family

ID=86613091

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280079174.4A Pending CN118317771A (zh) 2021-11-30 2022-11-29 用于局部治疗布鲁里溃疡中的溃疡分枝杆菌的制剂和方法

Country Status (5)

Country Link
US (1) US20240390366A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024544075A (cg-RX-API-DMAC10.html)
CN (1) CN118317771A (cg-RX-API-DMAC10.html)
AU (1) AU2022399569A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023102363A1 (cg-RX-API-DMAC10.html)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610198A (en) * 1994-03-18 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Anti-mycobacterial compositions and their use for the treatment of tuberculosis and related diseases
WO2007085057A1 (en) * 2006-01-25 2007-08-02 The Council Of The Queensland Institute Of Medical Research A medical protocol
GB0709513D0 (en) * 2007-05-17 2007-06-27 Helperby Therapeutics Ltd Topical formulations
US9018216B2 (en) * 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
WO2016179231A1 (en) * 2015-05-04 2016-11-10 Board Of Trustees Of Michigan State University Compositions and methods for inhibiting bacterial growth
US11572588B2 (en) * 2017-07-19 2023-02-07 The Regents Of The University Of Colorado, A Body Corporate Methods of evaluating treatment efficacy and/or treatment duration in mycobacterial diseases
WO2021184339A1 (en) * 2020-03-20 2021-09-23 Merck Sharp & Dohme Corp. Oxazolidinone compound and methods of use thereof as an antibacterial agent
CA3180160A1 (en) * 2020-04-17 2021-10-21 Shenzhen Pharmacin Co., Ltd Pharmaceutical compositions
JP7893751B2 (ja) * 2020-05-01 2026-07-22 マンカインド コーポレイション ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法

Also Published As

Publication number Publication date
JP2024544075A (ja) 2024-11-27
AU2022399569A1 (en) 2024-06-06
US20240390366A1 (en) 2024-11-28
WO2023102363A1 (en) 2023-06-08

Similar Documents

Publication Publication Date Title
JP3240330B2 (ja) コラン酸の塩を含有する医薬調合剤および化粧品調合剤
CN1320880C (zh) 改进的体内局部无创伤用制剂
JP2001526210A (ja) 親油性糖質副腎皮質ステロイドおよび界面活性剤を１つだけ含有するミセルを含んでなる医薬組成物
KR20200051854A (ko) 코르티코스테로이드를 포함하는 국소용 조성물
JP7572538B2 (ja) Ｊａｋ阻害剤およびラウレス－４を含有する局所配合物
JP2023522065A (ja) 医薬組成物
US20120022032A1 (en) Corticosteroid compositions and methods of treatments thereof
JPWO2006098353A1 (ja) 外用剤
HK40111713A (en) Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
US20230181591A1 (en) Stable formulations of shr0302
AU2022399569A1 (en) Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
JP4361789B2 (ja) 体表の過剰増殖疾患の処置
US20220040138A1 (en) Teriflunomide topical pharmaceutical compositions
HK40129829A (en) Treatment of uremic pruritus
WO2024159048A1 (en) Treatment of uremic pruritus
JP2023544728A (ja) 扁平苔癬の治療のための局所ルキソリチニブ
CN118660693A (zh) Shr0302的稳定制剂
US20210069214A1 (en) Topical compositions comprising a corticosteroid for the treatment of psoriasis in pediatric patients
JP2020055773A (ja) 油性外用液
CZ20002298A3 (cs) Farmaceutický prostředek, obsahující micely ve vodném prostředí, a způsob jeho přípravy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40111713

Country of ref document: HK